Published in Blood Weekly, September 28th, 2000
"Lentiviral vectors have the potential to play an important role in hemophilia gene therapy," stated F. Park and colleagues, Stanford University, California. "The present study used human immunodeficiency virus (HIV) based lentiviral vectors containing an EF1 alpha enhancer/promoter driving human factors VIII (hFVIII) or IX (hFIX) complementary DNA expression for portal vein injection into C57B1/6 mice."
They reported that increased doses of hFIX-expressing lentivirus resulted in a...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.